Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
Charged with protecting the innovation arising from MedImmune, the global biologics research and development arm of AstraZeneca, as well as AstraZeneca’s innovative medicines and early development biotech units, Scott Alban’s job is far from insignificant.
Alban was behind AstraZeneca and MedImmune’s recent transformation of its global IP organisation to circumvent geographic and cultural barriers between the IP professionals who support pharmaceuticals and biologics across seven global sites.
“We wanted to empower our attorneys and other patent professionals to work collaboratively across multiple therapy areas, technology platforms and therapeutic modalities,” he says.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Scott Alban, LSIPR 50 2018, AstraZeneca, MedImmune, biology, research and development, innovation, biotech